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Abstract
Background: Deficiency of adenosine deaminase 2 (DADA2) is a rare autosomal recessive autoinflammatory
condition. Recognised features include vasculitis predominantly affecting medium sized vessels, livedoid skin rash,
central and peripheral nervous system involvement, variable degrees of immunodeficiency, and marrow failure,
amongst other clinical presentations. We present the case of a six year old male with DADA2 who presented with
acute testicular ischaemia secondary to vasculitis, the first such description in DADA2.
Case presentation: A six year old male presented acute right-sided testicular pain. His history included transient
infantile neutropenia, resolved hepatosplenomegaly, and longstanding livedo racemosa, leading to screening and
confirmation of DADA2 caused by homozygous c.139G > C (p.G47R) mutation of ADA2. As his only clinical feature
was that of mild livedo racemosa with normal laboratory parameters at diagnosis, he was being actively monitored
prior to starting any treatment. At a routine clinic follow-up a 24 h history of testicular pain was noted on systems
review. He was afebrile, and his only physical signs were that of moderate livedo racemosa, and tenderness of the
right testicle. Laboratory parameters revealed C-reactive protein (CRP) 8 mg/L (reference range [RR] < 20 mg/L);
erythrocyte sedimentation rate (ESR) 28 mm/hr. (RR < 10); and serum amyloid A (SAA)5 mg/L (RR < 10). Ultrasound-
scan of the scrotum revealed significantly reduced perfusion of the right testes, without torsion. Surgical scrotal
exploration confirmed testicular ischaemia without torsion. Histology demonstrated ischaemic seminiferous tubules
with intervening haemorrhage and acute inflammatory cells, consistent with vasculitis of the testis as the cause. He
was treated with high dose intravenous methyl-prednisolone followed by a weaning course of oral prednisolone,
and subcutaneous adalimumab (anti-tumour necrosis factor alpha, anti-TNFα). Repeat ultrasound-scan 3 weeks later
revealed good testicular perfusion, with a small area of focal infarction. At last follow-up (11 months post-event) he
remained asymptomatic, on treatment with adalimumab.
Conclusion: The phenotype of DADA2 continues to expand, and we add testicular infarction to the features of
DADA2. CRP and SAA cannot be relied on as reliable biomarkers to predict tissue ischaemia and hence who to
target for anti-TNFα therapy in DADA2, since these remained steadfastly normal before, during, and after testicular
infarction in this case.
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Background
Deficiency of adenosine deaminase 2 (DADA2) is a re-
cently described recessive genetic autoinflammatory dis-
ease [1, 2], with variable clinical penetration and severity,
even in families with individuals sharing the same muta-
tion [3]. Commonly encountered clinical features include
systemic inflammation, recurrent fevers, various vasculitic
features resembling polyarteritis nodosa (PAN) including
livedo racemosa, vasculitic ulcers, and various other cuta-
neous vasculitic phenomena; and systemic vasculitis af-
fecting virtually any organ in the body but particularly the
neurological system with propensity to strokes (both lacu-
nar and haemorrhagic) [1, 2, 4, 5], and also the peripheral
nervous system [3]. DADA2 is also associated with varying
degrees of immunodeficiency (immunoglobulin defi-
ciency) [3], marrow failure, ranging from single cell lines
affected (pure red cell aplasia mimicking Diamond-
Blackfan anaemia; or neutropenia), through to complete
marrow failure [4, 6]. Lymphoproliferation mimicking
Castleman’s disease has also been described [7]. Whilst
designated an autoinflammatory disease, autoimmunity
has also been described in DADA2 [8]. Asymptomatic
(sometimes referred to as “pre-symptomatic”) adults with
DADA2 detected on genetic screening of index cases are
also recognised, further emphasising the lack of genotype/
phenotype correlation [3].
Bi-allelic loss-of-function mutation in ADA2 located
on chromosome 22q11.1 results in loss of enzyme activ-
ity of adenosine deaminase 2 (ADA2) [1, 2], a dimeric
57 kDa extracellular isoform of adenosine deaminase 1
(ADA1: deficiency of which causes severe combined im-
munodeficiency) [1, 9, 10]. Despite its name, the adeno-
sine deaminase enzyme activity of ADA2 is 100-fold
lower than ADA1, although this rises at higher tempera-
tures and acid pH [9]. Whilst the function of ADA2 is
still poorly understood, this is an area of intense ongoing
research. The current consensus view is that although
the receptor for ADA2 has not yet been identified [11],
the main role of ADA2 is probably that of a growth fac-
tor influencing the haematopoietic system, a function
which is possibly independent of its adenosine deami-
nase enzymatic activity [1, 9]. Patients with DADA2
demonstrate skewing towards pro-inflammatory M1
macrophage populations, with relative paucity of anti-
inflammatory M2 macrophages [1]. These M1 macro-
phages produce several pro-inflammatory cytokines, and
interact with endothelium to initiate vasculitis [1, 10].
There has never been a randomised, controlled thera-
peutic clinical trial for the treatment of DADA2. Despite
that, there is a very strong prevalent clinical experience
suggesting therapeutic benefit for TNF blockade (anti-
TNF; often combined with corticosteroids at therapy ini-
tiation), with no reports of cardiovascular events occur-
ring in patients treated with adequate doses of anti-TNF
[2–4, 12]. Although almost certainly a poly-cytokine dis-
ease, the same is not true of IL-6 blockade, since pa-
tients have been described with vasculitic events
(including stroke) whilst on tocilizumab [3]. Likewise,
interleukin-1 blockade anecdotally is not effective for in-
flammatory sequelae of DADA2, although canakinumab
might be effective for AA amyloidosis secondary to
DADA2 [13]. Allogeneic haematopoietic stem cell trans-
plantation (HSCT) can be effective for selected patients
with marrow failure and/ or severe immunodeficiency;
vasculitic and other autoinflammatory features also re-
spond completely to HSCT [14].
We present the first description of vasculitic testicular
infarction in a child with DADA2, thus expanding the
phenotype even further, and highlight controversies and
current unmet needs for this newly described genetic
autoinflammatory disease.
Case presentation
A six year old Indian male born to non-consanguineous
parents presented for routine outpatient review for mon-
itoring of deficiency of adenosine deaminase 2 (DADA2)
. On systems review, he had a 24-h history of nausea
and vomiting, followed by acute, moderate right-sided
testicular pain, without fever.
His past medical history included an isolated episode
of transient neutropenia as an infant, in association with
hepatosplenomegaly which was considered at the time
to be due to intercurrent viral infection. These features
resolved completely, but at the age of 5 years he was re-
ferred to our centre with lower limb rash considered to
be cutaneous PAN. Examination revealed typical livedo
racemosa mainly involving the lower limbs, with no
other abnormalities detected on full examination of all
systems. Consequently, genetic screening of ADA2 and
assessment of serum ADA2 enzyme activity was under-
taken. These revealed homozygous c.139G > C mutation
(p.G47R) of ADA2, and absent (i.e. undetectable) serum
ADA2 enzyme activity, detected as part of routine care,
as previously described by our group [3], confirming the
diagnosis of DADA2. His parents were heterozygous for
the same mutation; a 3 year old female sibling was bi-
allelic wild type for ADA2; and there was no family his-
tory of vasculitis, autoimmunity or immunodeficiency.
Investigations performed prior to the acute presentation
as part of general workup for DADA2 revealed: normal
complete blood count (including normal differential
white cell counts); normal renal and liver function;
serum amyloid A (SAA) 8.2 mg/L (reference range [RR]
< 10mg/L); C-reactive protein (CRP) < 5 mg/L (RR < 20
mg/L); erythrocyte sedimentation rate (ESR) < 10mm/
hour (RR < 10mm/hour); normal coagulation screen;
negative viral hepatitis screen; normal immunoglobulin
G, A, and M levels; negative screening for coeliac
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disease; negative autoantibody screening (Anti-nuclear
antibodies (ANA) double-stranded deoxyribonucleic acid
(DNA), ANCA (Anti-neutrophil cytoplasmic antibodies)
rheumatoid factor, and thyroid peroxidase antibodies);
and normal brain and brainstem magnetic resonance im-
aging, and magnetic resonance angiography. Since his
only clinical feature was mild cutaneous involvement,
and he was otherwise completely asymptomatic and with
completely normal laboratory and imaging workup, he
was kept under close surveillance without treatment,
since it is known that DADA2 can vary considerably in
clinical severity, with adult asymptomatic cases de-
scribed previously [3].
At the acute presentation, he was afebrile and haemo-
dynamically stable. Systemic examination including full
neurological examination was normal except for livedo
racemosa on his lower limbs (Fig. 1). He was also noted
to have a mildly swollen and tender right testicle, but
without typical clinical features of torsion. Repeat la-
boratory workup revealed a normal full blood count
(haemoglobin 125 g/L; total white cell count 6.56 X109/L
[RR 5–15]; platelets 306 X109/L [RR150–450]); normal
liver, renal and coagulation profile. ESR was mildly ele-
vated at 28 mm/hr. [RR < 10]; CRP of 17 mg/L [RR < 20];
and SAA 5mg/L (RR < 10). Screening for antiphospholi-
pid syndrome was negative for lupus anticoagulant (nor-
mal direct Russell Viper venom test; and negative
anticardiolipin IgG autoantibodies). Ultrasound-scan
(USS) of the testes showed significantly reduced perfu-
sion of the right testes compared to the left (Fig. 2), with
no suspicion of torsion. He underwent an urgent surgi-
cal exploration and testicular biopsy. There was no evi-
dence of testicular torsion found intraoperatively.
Histology showed ischaemic seminiferous tubules with
intervening haemorrhage and acute inflammatory cells
which was consistent with an underlying vasculitic
process, although no vessels were visible in the specimen
to confirm that definitively (Fig. 3). Post-operatively, he
was pulsed with intravenous methyl-prednisolone (30
mg per kilogram for 3 consecutive days); followed by 2
mg per kilogram of daily oral prednisolone tapering off
over 6 weeks; adalimumab 20 mg subcutaneously every
2 weeks (dose-banded, based on weight of 27.4Kg); and
anti-aggregant dose of aspirin, 75 mg daily. He recovered
well from the surgery and was discharged on post-
operative day 3. Repeat USS at three weeks showed good
perfusion of the testicular parenchyma on the right, with
a small area of focal infarction. At last follow-up (11
months after the acute presentation) he remains well on
40mg of adalimumab every 2 weeks (weight now 32 kg),
and daily aspirin. Apart from the mild elevation of ESR
detected on the day of presentation with testicular is-
chaemia, all blood tests including CRP and SAA have
remained steadfastly within the reference range before,
during, and after testicular infarction (Fig. 4).
Discussion and conclusions
We present the first description of vasculitic testicular
infarction in a child with DADA2, thus expanding the
phenotype even further. Our case highlights a number
of important ongoing controversies and challenges re-
garding the management of DADA2, namely: lack of any
biomarker to monitor patients for risk of vasculitic
events, and hence when to initiate (arguably, lifelong)
treatment with anti-TNF; controversies around the use
of aspirin in DADA2; and lack of routine availability and
reimbursement for anti-TNF treatment in patients with
DADA2 in some countries.
DADA2 is heterogeneous in its severity with distinct
lack of genotype/ phenotype correlation, and reports of
adult patients with typical mutations and absence of
ADA2 enzyme activity without any symptoms or signs.
It has hitherto been assumed that presence of systemic
inflammation would be an obvious indicator of need for
Fig. 1 Livedo racemosa noted on both lower limbs
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treatment, and also other haematological and immuno-
logical manifestations such as marrow failure or im-
munodeficiency. This case illustrates that patients with
absolutely normal laboratory parameters may also be at
risk of developing acute ischaemic events, with appar-
ently no obvious clinical triggers. Thus the negative pre-
dictive value for ischaemic events of CRP or SAA would
be suggested to be low based on this case, since these
were steadfastly within the normal reference range be-
fore, during, and after acute testicular infarction. We ob-
served a transient rise of ESR on the day of tissue
infarction, perhaps secondary to tissue injury. This indi-
cates that conventional acute phase reactants are not ne-
cessarily predictive of disease activity and hence risk of
severe events such as tissue infarction. In the future, this
might be offered by peripheral blood cytokine analyses,
peripheral blood cell transcription signals such as type I
interferon regulated gene expression [15], recently sug-
gested as a biomarker of disease activity in DADA2 [16],
novel proteomics, or even some as yet undescribed bio-
marker derived from experience in other vasculitides
such as circulating endothelial cells or endothelial mi-
croparticles [17–19].
Lack of a robust prognostic or disease activity bio-
marker predictive of adverse clinical outcomes makes
therapeutic decisions for DADA2 difficult. One approach
is to offer treatment with anti-TNF to all patients
DADA2 upon diagnosis, even without any evidence of
Fig. 2 Doppler study of both testes (transverse views) showing globally reduced (but not absent) perfusion in the right testes compared to the left
Fig. 3 Photomicrograph of testicular biopsy showing patchy areas of tubular necrosis with loss of cellular and nuclear detail and nuclear
‘smudging’ (Right side) with more normal, viable tubules (Left side); haematoxylin and eosin, original magnification × 100
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severe systemic vasculitis or autoinflammation. Argu-
ably, in this case, this approach might have prevented
testicular infarction. The downside is that this would re-
sult in initiation of expensive and lifelong immunosup-
pressive treatment for some patients who may never
experience a clinical event, or who’s clinical event may
be decades henceforth.
There has never been a randomised control thera-
peutic trial for DADA2, perhaps unsurprising since the
disease was only first described in March 2014 [1, 2],
and only approximately 200 cases are known about
worldwide according to a recent patient registry curated
by the DADA2 Foundation (http://www.dada2.org).
Emphasising the rarity of the condition, and therefore
the difficulties that would be encountered when consid-
ering performing a randomised controlled trial of fre-
quentist statistical design. Consequently, anti-TNF is not
routinely available for patients with DADA2 in the UK,
even for those with severe symptoms.
Thus, countries which currently do not have policies
for the routine prescribing and reimbursement of anti-
TNF for patients with DADA2 need to consider an in-
creasingly compelling “real-world” evidence in relation
to the therapeutic benefit of anti-TNF in DADA2 par-
ticularly in relation to the prevention of stroke events.
Recently, Ombrello et al. described outcomes in relation
to anti-TNF treatment in their cohort of DADA2 pa-
tients at the National Institute of Health [12]. Pre-anti-
TNF initiation, 55 strokes were observed in 15 patients
over 2077 patient months. This fell to 0 stroke events
over 733 patient months post anti-TNF initiation, a
highly statistically significant finding clearly illustrating
the benefit of anti-TNF for the prevention of strokes in
DADA2 in a real-world setting. No hard data favour the
use of one anti-TNF agent over another [3], although
some physicians advocate the use of monoclonal anti-
bodies against TNF rather than etanercept or etanercept-
biosimilars, possibly based on suboptimal outcomes using
etanercept in clinical trials for other vasculitides [20].
Two other important therapeutic points require some
commentary. Our patient received corticosteroids and
antiplatelet doses of aspirin. The rationale for corticoste-
roids to treat acute ischaemic events in DADA2 is to
switch off vasculitis as quickly as possible, since the
pathology is that of vascular occlusion secondary to vas-
culitis, often with platelet and endothelial activation in
the context of systemic vasculitic inflammation, as previ-
ously described for other vasculitides [21–24]. Luminal
arterial occlusion leading to reduced organ perfusion
(Fig. 2), occurs from thrombotic occlusion, with or with-
out a background of chronic luminal narrowing from
vascular remodelling from chronic vasculitis, as seen in
PAN [25]. Whilst the use of corticosteroids in DADA2 is
based on experience gleaned from the treatment of other
vasculitides [26–29], the additional therapeutic benefit of
this approach versus anti-TNF alone is uncertain. Re-
garding aspirin, the rationale for this is again target the
aforementioned platelet activation, with contribution to
thrombus formation and luminal occlusion, as is the
case for other vasculitides such as Kawasaki disease [30].
The particular concern of this approach, however, is that
patients with DADA2 may present with haemorrhagic
Fig. 4 Acute phase markers before, during, and after acute testicular infarction in DADA2. Acute phase responses were completely normal prior
to testicular infarction. C-reactive protein (CRP) and serum amyloid A (SAA) remained within the normal range throughout the episode and
follow-up. Erythrocyte sedimentation rate (ESR) was normal (measured only once prior to the acute presentation), but was transiently modestly
elevated on the day of tissue infarction (arrowed), remaining normal at follow-up (see main text for treatment received)
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stroke (with or without thrombocytopenia) and thus as-
pirin would be contraindicated in that situation; or in
the case of lacunar stroke, that the use of aspirin might
result in haemorrhagic extension and clinical deterior-
ation. In this case, with clear demonstration of acute tes-
ticular ischaemia and reduced perfusion, judicious use of
anti aggregant dose of aspirin with careful monitoring
for haemorrhagic extension seemed logical and safe, as
borne out by the favourable clinical outcome.
Our case highlights the ever-expanding phenotype of
DADA2, and highlights current therapeutic challenges.
Improvements in our understanding of the pathogenesis
will ultimately lead to better biomarkers, better treat-
ments, and ultimately even cure using gene therapy
based on the favourable clinical outcomes of patients
undergoing allogeneic HSCT thus far.
Conclusion
This is the first reported case of testicular ischaemia in
the context of ADA-2 deficiency.
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